Laurits Sebastian Dahl, Ann Søegaard Knoop, Maj-Britt Jensen, Eva Harder, Jeanette Dupont Rønlev, Tobias Berg
{"title":"图卡替尼治疗丹麦人表皮生长因子受体2阳性转移性乳腺癌的实际疗效。","authors":"Laurits Sebastian Dahl, Ann Søegaard Knoop, Maj-Britt Jensen, Eva Harder, Jeanette Dupont Rønlev, Tobias Berg","doi":"10.61409/A11240821","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB trial. In this short report, we evaluate the extent and efficacy of tucatinib treatment among Danish patients.</p><p><strong>Methods: </strong>This is a retrospective study that includes all known Danish patients who initiated tucatinib prior to June 1, 2024. We utilised the nationwide clinical database of the Danish Breast Cancer.</p><p><strong>Results: </strong>In total, 38 patients were treated. Nineteen (50%) of the patients had central nervous system (CNS) metastases, and 21 (55%) had visceral disease. Median progression-free survival was 8.7 months (95% CI: 6.2; 13.3) and median overall survival was 22.4 months (95% CI: 13.1; N/A). Nine patients exhibited a performance status of 2-3 (n = 5) or uncontrollable CNS metastases (n = 4), not meeting the inclusion criteria applied in the HER2CLIMB trial.</p><p><strong>Conclusions: </strong>Our results align with data presented from the HER2CLIMB trial. Considerably fewer patients than initially expected have been treated in Denmark.</p><p><strong>Funding: </strong>None.</p><p><strong>Trial registration: </strong>Approved by the Capital Regions Research Overview (P-2024-175774) and the Centre for Health Research (R-24065900).</p>","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"72 10","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.\",\"authors\":\"Laurits Sebastian Dahl, Ann Søegaard Knoop, Maj-Britt Jensen, Eva Harder, Jeanette Dupont Rønlev, Tobias Berg\",\"doi\":\"10.61409/A11240821\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB trial. In this short report, we evaluate the extent and efficacy of tucatinib treatment among Danish patients.</p><p><strong>Methods: </strong>This is a retrospective study that includes all known Danish patients who initiated tucatinib prior to June 1, 2024. We utilised the nationwide clinical database of the Danish Breast Cancer.</p><p><strong>Results: </strong>In total, 38 patients were treated. Nineteen (50%) of the patients had central nervous system (CNS) metastases, and 21 (55%) had visceral disease. Median progression-free survival was 8.7 months (95% CI: 6.2; 13.3) and median overall survival was 22.4 months (95% CI: 13.1; N/A). Nine patients exhibited a performance status of 2-3 (n = 5) or uncontrollable CNS metastases (n = 4), not meeting the inclusion criteria applied in the HER2CLIMB trial.</p><p><strong>Conclusions: </strong>Our results align with data presented from the HER2CLIMB trial. Considerably fewer patients than initially expected have been treated in Denmark.</p><p><strong>Funding: </strong>None.</p><p><strong>Trial registration: </strong>Approved by the Capital Regions Research Overview (P-2024-175774) and the Centre for Health Research (R-24065900).</p>\",\"PeriodicalId\":11119,\"journal\":{\"name\":\"Danish medical journal\",\"volume\":\"72 10\",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Danish medical journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.61409/A11240821\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A11240821","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Real-world efficacy of tucatinib in Danish human epidermal growth factor receptor 2-positive metastatic breast cancer.
Introduction: Tucatinib in combination with trastuzumab and capecitabine is approved for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer in third-line and later based on the results of the HER2CLIMB trial. In this short report, we evaluate the extent and efficacy of tucatinib treatment among Danish patients.
Methods: This is a retrospective study that includes all known Danish patients who initiated tucatinib prior to June 1, 2024. We utilised the nationwide clinical database of the Danish Breast Cancer.
Results: In total, 38 patients were treated. Nineteen (50%) of the patients had central nervous system (CNS) metastases, and 21 (55%) had visceral disease. Median progression-free survival was 8.7 months (95% CI: 6.2; 13.3) and median overall survival was 22.4 months (95% CI: 13.1; N/A). Nine patients exhibited a performance status of 2-3 (n = 5) or uncontrollable CNS metastases (n = 4), not meeting the inclusion criteria applied in the HER2CLIMB trial.
Conclusions: Our results align with data presented from the HER2CLIMB trial. Considerably fewer patients than initially expected have been treated in Denmark.
Funding: None.
Trial registration: Approved by the Capital Regions Research Overview (P-2024-175774) and the Centre for Health Research (R-24065900).
期刊介绍：
The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content.
DMJ will publish the following articles:
• Original articles
• Protocol articles from large randomized clinical trials
• Systematic reviews and meta-analyses
• PhD theses from Danish faculties of health sciences
• DMSc theses from Danish faculties of health sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
